RxDoctor Payments Data

Marta San Luciano, MD

Neurology · San Francisco, CANPI 1407806250

Payments from drug & device makers

$5,210in general payments, 2019–2025

Across 77 payments — averaging $67.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Biogen$2K
  • Medtronic$1K
  • AbbVie$218
  • Ipsen Biopharmaceuticals, Inc$165
  • Piramal Critical Care$42
  • plus $103 from 5 others

What the payments were for

  • Consulting fees$75014%
  • Speaking & faculty fees$260%
  • Travel & lodging$1,18023%
  • Food & beverage$3,25462%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific17$1,788
Biogen15$1,764
Medtronic(2 entities)23$1,130
AbbVie(2 entities)9$218
Ipsen Biopharmaceuticals, Inc6$165
Piramal Critical Care2$42
Abbott1$28
Acorda Therapeutics, Inc1$26
Merz North America, Inc.1$19
Amneal Pharmaceuticals LLC1$15
Neurocrine Biosciences, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,210 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$58,292
Medicare patients
171
Services billed
636

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate21$184,603
RytaryCarbidopa/Levodopa108$151,935
NuplazidPimavanserin Tartrate24$121,077
NourianzIstradefylline15$38,768
OngentysOpicapone47$33,624
GocovriAmantadine Hcl15$27,647
Carbidopa-LevodopaCarbidopa/Levodopa297$13,759
Carbidopa-Levodopa ErCarbidopa/Levodopa184$12,886
Rasagiline Mesylate50$8,131
AmantadineAmantadine Hcl46$7,401
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone14$6,624
Entacapone36$6,151
Baclofen24$4,280
Rivastigmine14$3,547
Selegiline Hcl19$2,712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$15$218,22768 claims
Amneal Pharmaceuticals LLCRytary$15$151,935108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,996 neurology providers in California.

Other neurology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →